Sort:
Open Access Clinical Medicine Issue
Relationship between clonal hematopoiesis of indeterminate potential and severity of coronary stenosis in coronary heart disease patients with renal insufficiency
Journal of Army Medical University 2024, 46(24): 2765-2771
Published: 30 December 2024
Abstract PDF (539.9 KB) Collect
Downloads:0
Objective

To investigate the association between clonal hematopoiesis of indeterminate potential (CHIP) and the severity of coronary artery lesions in coronary heart disease (CHD) patients with renal insufficiency.

Methods

A case-control trial was conducted on 70 CHD patients with renal insufficiency admitted in Chongqing Emergency Medical Center (Affiliated Central Hospital of Chongqing University) and Department of Cardiovascular Diseases of the First Affiliated Hospital of Chongqing Medical University from December 2023 to July 2024.According to the median Gensini score, they were classified into the Gensini score < 44 group (n=34) and ≥44 group (n=36), and based on carrying CHIP mutation or not, they were divided into CHIP group (n=23) and non-CHIP group (n=47).The differences in clinical data were compared between the above 2 pair groups respectively.Binary logistic regression analysis was used to assess the relationship between CHIP status and the severity of coronary artery lesions.

Results

Compared with the Gensini score < 44 group, the Gensini score ≥44 group had a higher CHIP carriage rate (17.2%vs 47.6%, P=0.008) as well as NT-proBNP level (767 vs 3480 ng/L, P=0.039).Binary logistic regression analysis showed that CHIP status was still associated with higher Gensini scores after adjustment of NT-proBNP (OR=3.935, 95%CI=1.153~13.435, P=0.029).Further CHIP grouping results suggested that the patients in the CHIP group had higher Gensini score (48 vs 38, P=0.004), larger proportion of 3-vessle disease (52.2%vs 25.5%, P=0.040), and lower left ventricular ejection fraction (55.0%vs 58.0%, P=0.042) than those in the non-CHIP group.

Conclusion

CHIP is an independent risk factor for severe coronary artery disease in CHD patients with renal insufficiency.

Open Access Review Issue
Neutrophils and neutrophil extracellular traps in ischaemia–reperfusion injury: pathophysiological roles and therapeutic potential
Burns & Trauma 2026, 14(3): tkag022
Published: 16 March 2026
Abstract PDF (2.8 MB) Collect
Downloads:0

Ischaemia–reperfusion injury (IRI) is a fundamental pathological process underlying acute and chronic damage associated with myocardial infarction, ischaemic stroke, and solid organ transplantation. Although timely reperfusion is indispensable for tissue salvage, it paradoxically promotes maladaptive immune activation and oxidative stress, which aggravate microvascular dysfunction and organ failure. Accumulating evidence indicates that sterile inflammation, endothelial injury, and immunothrombosis are the central drivers of IRI progression. Among innate immune effectors, neutrophils act as first responders that integrate chemotactic signalling, adhesion cascades, and metabolic rewiring. Upon activation, neutrophils release damage-associated molecular patterns and form neutrophil extracellular traps (NETs), which amplify inflammation, promote coagulation, and disrupt tissue repair across organs. However, the organ-specific roles, temporal dynamics, and translational relevance of neutrophils and NETs in IRI remain incompletely understood. In this review, we systematically dissect the neutrophil- and NET-mediated mechanisms involved in IRI across the heart, brain, kidney, liver, and transplanted organs, with a particular emphasis on endothelial crosstalk, immunothrombosis, and metabolic regulation. We further summarize emerging NET-associated biomarkers—including cell-free DNA and myeloperoxidase–DNA complexes—for IRI diagnosis and prognosis. Finally, we evaluate therapeutic strategies targeting neutrophil recruitment, immune metabolism, and NET clearance, highlighting challenges for clinical translation. In summary, this review provides a mechanistic and translational framework for targeting neutrophils and NETs in precision therapies for IRI.

Total 2